TR200200913T2 - Bir NK1 reseptörü antagonistini ve bir gaba yapısal analoğunun sinerjik kombinasyonları. - Google Patents

Bir NK1 reseptörü antagonistini ve bir gaba yapısal analoğunun sinerjik kombinasyonları.

Info

Publication number
TR200200913T2
TR200200913T2 TR2002/00913T TR200200913T TR200200913T2 TR 200200913 T2 TR200200913 T2 TR 200200913T2 TR 2002/00913 T TR2002/00913 T TR 2002/00913T TR 200200913 T TR200200913 T TR 200200913T TR 200200913 T2 TR200200913 T2 TR 200200913T2
Authority
TR
Turkey
Prior art keywords
receptor antagonist
synergistic combinations
structural analog
gaba
gaba analog
Prior art date
Application number
TR2002/00913T
Other languages
English (en)
Inventor
Hughes John
Singh Lakhbir
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of TR200200913T2 publication Critical patent/TR200200913T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Mevcut bulus bir NK1 reseptörü antagonistinin ve bir GABA analogunun sinerjik kombinasyonlarinin kullanildigi bir tedavi ve NK1 reseptörü antagonistini ve GABA analogunu içeren farmasötik bilesimler ve ürünler saglamaktadir. Mevcut bulus ayrica kronik agrinin önlenmesi veya tedavi edilmesi için olan bir ilacin hazirlanmasinda bir NK1 reseptörü antagonistinin ve bir GABA analogunun kullanimi saglamaktadir.
TR2002/00913T 1999-10-07 2000-10-05 Bir NK1 reseptörü antagonistini ve bir gaba yapısal analoğunun sinerjik kombinasyonları. TR200200913T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15827199P 1999-10-07 1999-10-07

Publications (1)

Publication Number Publication Date
TR200200913T2 true TR200200913T2 (tr) 2002-09-23

Family

ID=22567369

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00913T TR200200913T2 (tr) 1999-10-07 2000-10-05 Bir NK1 reseptörü antagonistini ve bir gaba yapısal analoğunun sinerjik kombinasyonları.

Country Status (38)

Country Link
EP (2) EP1221950B1 (tr)
JP (2) JP2003510356A (tr)
KR (1) KR20020060192A (tr)
CN (1) CN1387434A (tr)
AP (1) AP2002002501A0 (tr)
AR (1) AR029646A1 (tr)
AT (1) ATE269072T1 (tr)
AU (2) AU7663300A (tr)
BG (1) BG106548A (tr)
BR (1) BR0014598A (tr)
CA (1) CA2385930A1 (tr)
CO (1) CO5280195A1 (tr)
CR (1) CR6614A (tr)
CZ (1) CZ20021116A3 (tr)
DE (1) DE60011650T2 (tr)
DK (1) DK1221950T3 (tr)
EA (1) EA004266B1 (tr)
EE (1) EE200200185A (tr)
ES (1) ES2220542T3 (tr)
GT (1) GT200000166A (tr)
HR (1) HRP20020286A2 (tr)
HU (1) HUP0203466A3 (tr)
IL (1) IL148965A0 (tr)
IS (1) IS6318A (tr)
MA (1) MA26826A1 (tr)
MX (1) MXPA02003484A (tr)
NO (1) NO20021625D0 (tr)
NZ (1) NZ517949A (tr)
OA (1) OA12063A (tr)
PA (1) PA8504301A1 (tr)
PE (1) PE20010708A1 (tr)
PL (1) PL357498A1 (tr)
PT (1) PT1221950E (tr)
SK (1) SK4542002A3 (tr)
TR (1) TR200200913T2 (tr)
UY (1) UY26376A1 (tr)
WO (2) WO2001024792A1 (tr)
ZA (1) ZA200202675B (tr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934061B3 (en) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba and its derivatives for the treatment of pain
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA04011529A (es) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
US20060039968A1 (en) * 2002-10-08 2006-02-23 Ramalingam Manikandan Gabapentin tablets and method for their preparation
US20060264509A1 (en) * 2003-03-21 2006-11-23 Fraser Matthew O Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
KR100742001B1 (ko) * 2003-03-21 2007-07-23 다이노젠 파마세우티컬스, 인코포레이티드 평활근 모듈레이터 및 알파2 델타 서브유닛 칼슘 채널모듈레이터를 이용한 하부 요로 질환의 치료 방법
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
KR101786818B1 (ko) 2010-07-30 2017-10-18 도레이 카부시키가이샤 신경장애성 동통의 치료제 또는 예방제
CN107050456B (zh) * 2010-09-28 2022-08-12 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
FI3946260T3 (fi) * 2019-03-26 2026-03-24 Orion Corp Pregabaliiniformulaatioita ja niiden käyttö
WO2022234110A1 (en) * 2021-05-07 2022-11-10 Plus Vitech, S.L. Gamma-aminobutyric acid derivatives for use in cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
AU726745B2 (en) * 1996-10-07 2000-11-16 Merck Sharp & Dohme Limited CNS-penetrant NK-1 receptor antagonists as antidepressant and/or an anti-anxiety agent
CA2273785A1 (en) * 1996-12-02 1998-06-11 Raymond Baker Use of nk-1 receptor antagonists for treating severe anxiety disorders

Also Published As

Publication number Publication date
BR0014598A (pt) 2002-06-11
PT1221950E (pt) 2004-08-31
PA8504301A1 (es) 2002-08-26
JP2003510356A (ja) 2003-03-18
HRP20020286A2 (en) 2003-08-31
ZA200202675B (en) 2003-04-15
EP1221950B1 (en) 2004-06-16
WO2001024791A1 (en) 2001-04-12
ATE269072T1 (de) 2004-07-15
AP2002002501A0 (en) 2002-06-30
BG106548A (en) 2002-12-29
UY26376A1 (es) 2000-12-29
IL148965A0 (en) 2002-11-10
WO2001024792A9 (en) 2002-09-06
AU7663300A (en) 2001-05-10
SK4542002A3 (en) 2003-09-11
KR20020060192A (ko) 2002-07-16
JP2003510355A (ja) 2003-03-18
CO5280195A1 (es) 2003-05-30
DK1221950T3 (da) 2004-09-20
PL357498A1 (en) 2004-07-26
OA12063A (en) 2006-05-03
NO20021625L (no) 2002-04-05
HUP0203466A3 (en) 2005-03-29
HUP0203466A2 (hu) 2003-02-28
NO20021625D0 (no) 2002-04-05
PE20010708A1 (es) 2001-07-27
GT200000166A (es) 2002-03-30
ES2220542T3 (es) 2004-12-16
AU1696201A (en) 2001-05-10
MXPA02003484A (es) 2004-09-10
CA2385930A1 (en) 2001-04-12
CN1387434A (zh) 2002-12-25
EP1233766A1 (en) 2002-08-28
IS6318A (is) 2002-03-21
EA004266B1 (ru) 2004-02-26
NZ517949A (en) 2003-08-29
EA200200303A1 (ru) 2002-08-29
CZ20021116A3 (cs) 2003-05-14
DE60011650D1 (de) 2004-07-22
MA26826A1 (fr) 2004-12-20
EE200200185A (et) 2003-04-15
WO2001024792A1 (en) 2001-04-12
AR029646A1 (es) 2003-07-10
EP1221950A1 (en) 2002-07-17
DE60011650T2 (de) 2005-07-14
CR6614A (es) 2003-12-04

Similar Documents

Publication Publication Date Title
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
HUP0202319A3 (en) Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
WO2003094836A3 (en) Methods and products for enhancing immune responses using imidazoquinoline compounds
WO2001078698A3 (en) Use of ngf-antagonists for the prevention or treatment of chronic visceral pain
TR200201067T2 (tr) Bir tramadol maddesi ve bir antikonvülsan ilaç içeren bileşimler
AP2000001785A0 (en) Medicaments
TR200002541T2 (tr) Topiramatın farmasötik bilişimi
BR0015188A (pt) Composições farmacêuticas
SI1546127T1 (sl) Novi pirimidinamidni derivati in njihova uporaba
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
AU7226301A (en) Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
MXPA02003484A (es) Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba.
IL133632A (en) Use of a specific 5ht2 receptor antagonist for the preparation of pharmaceutical compositions useful in the treatment of the sleep apnea syndrome
PT1656131E (pt) Utilização de betaína para tratar claudicação intermitente
TR200102512T2 (tr) Tüm ruhsal bozukluklar, adaptasyon bozuklukları ve çeşitli kaygı-depresyon bozukluklarının tedavisinde ya da önlenmesinde yararlı tıbbi ürünlerin hazırlanması için saredutan ve onun farmasötik olarak kabul edilebilir tuzlarının kullanımı.
IL156069A0 (en) Use of a substance which binds to sarp-1 receptor or influences the activity of endogenous sarp-1 in scleroderma
BR0007686A (pt) Uso de antagonistas receptores da angiotensina ii para tratar enfartação miocárdia aguda
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
BR0113886A (pt) Composição, composição farmacêutica, tratamento de combinação para prevenir ou inibir a geração ou atividade de trombina num paciente, método para inibir ou prevenir a geração ou atividade de trombina num paciente, uso de uma composição ou tratamento de combinação, uso de uma composição, uso e kit
MY138502A (en) Novel alkansulfonamides as endothelin antagonists
GB0211230D0 (en) Treatment of heart failure
PT942729E (pt) Utilizacao de antagonistas de receptores nk-1 para tratamento de doencas do stresse
GB9917290D0 (en) Pharmaceutical composition